Abstract
Late-stage cancer immunotherapy trials often lead to unusual survival curve shapes, like delayed curve separation or a plateauing curve in the treatment arm. It is critical for trial success to anticipate such effects in advance and adjust the design accordingly. Here, we use in silico cancer immunotherapy trials – simulated trials based on three different mathematical models – to assemble virtual patient cohorts undergoing late-stage immunotherapy, chemotherapy, or combination therapies. We find that all three simulation models predict the distinctive survival curve shapes commonly associated with immunotherapies. Considering four aspects of clinical trial design – sample size, endpoint, randomization rate, and interim analyses – we demonstrate how, by simulating various possible scenarios, the robustness of trial design choices can be scrutinized, and possible pitfalls can be identified in advance. We provide readily usable, web-based implementations of our three trial simulation models to facilitate their use by biomedical researchers, doctors, and trialists.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JC was funded by the Radboudumc. CF received an ERC Adv Grant ARTimmune (834618) and an NWO Spinoza grant. IV received an NWO-Vici grant (918.14.655). JT and AA were supported by a Young Investigator Grant (10620) from the Dutch Cancer Society. JT and GS were also supported by NWO grant VI.Vidi.192.084.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We have added two additional mathematical models of cancer immunotherapy by other authors to the manuscript and we show that despite considerable differences between the models, the results are indeed broadly similar. We simplified our initial mathematical model (now model M1) and re-did all analyses. We account for a likely treatment effect when fitting our models to the lung cancer cohort. To make the methodology proposed in this paper more readily useable, we provide both a simple web-based implementation (usable by anyone with a web browser) and a fast R package to perform in silico immunotherapy trials using the three mathematical models we implemented.
Data Availability
The code is available at GitHub: https://github.com/jeroencreemers/in-silico-clinical-trials
List of abbreviations
- ICI
- immune checkpoint inhibitor
- NCCTG
- North Central Cancer Treatment Group
- ODE
- ordinary differential equation
- OS
- overall survival
- PHA
- proportional hazard assumption
